ArticleProceedings of the National Academy of Sciences of the United States of America2018
Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 135 citations in OpenAlex.
- Assessment and detection of nucleotide excision repair capability in human cells: a critical review of current functional methods.Molecular biology reports · 2026Review
- Circadian Controlled Transcription in Brain and Peripheral Organs of Juvenile and Adult Mice.International journal of molecular sciences · 2026Article
- Protective role of Actovegin against Cisplatin-evoked testicular damage: evidence from a rat model.Journal of molecular histology · 2026Article
- Targeting the Golgi apparatus enhances PD-L1 blockade and synergizes with oxaliplatin to improve immunotherapy efficacy.The Journal of biological chemistry · 2026Article
- Asperosaponin VI Alleviates Cisplatin-Induced Liver Injury Through the Nrf2/HO-1 Signaling Pathway.Immunity, inflammation and disease · 2026Article
- SERBP1 is required for efficient HR repair and cisplatin chemoresistance in lung adenocarcinoma.Cell death discovery · 2026Article
- Biochemical mechanism of the mammalian circadian clock.FEBS letters · 2026Review
- Arrhythmic expression signatures of circadian clock-associated transcription factors and chronic circadian disruption contribute to advanced prostate cancer growth.International journal of cancer · 2026Article
- Circadian clock and cancer.Military Medical Research · 2026Review
- Dihydromyricetin protects against cisplatin-induced renal injury and mitochondria-mediated apoptosis via the EGFR/HSP27/STAT3 signaling pathway.Renal failure · 2025Article
- The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.Annals of medicine · 2025Review
- Time of Day-Dependent Responses to Cisplatin Treatment in a Male Mouse Model of Hepatoma.Journal of biological rhythms · 2025Article
- Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo.Molecular biology reports · 2025Article
- Article
- The impact of circadian rhythm disruption on oxaliplatin tolerability and pharmacokinetics in Cry1Archives of toxicology · 2025Article
- Single-nucleotide-resolution genomic maps of O6-methylguanine from the glioblastoma drug temozolomide.Nucleic acids research · 2025Article
- RIPK4 Downregulation Reduces ABCG2 Expression, Increasing BRAF-Mutated Melanoma Cell Susceptibility to Cisplatin- and Doxorubicin-Induced Apoptosis.Biomolecules · 2024Article
- Mechanism of dexmedetomidine protection against cisplatin induced acute kidney injury in rats.Renal failure · 2024Article
- Nucleotide excision repair of aflatoxin-induced DNA damage within the 3D human genome organization.Nucleic acids research · 2024Article
- MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma.Oncology letters · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
Abstract
Cisplatin is a major cancer chemotherapeutic drug. It kills cancer cells by damaging their DNA, mainly in the form of Pt-d(GpG) diadducts. However, it also has serious side effects, including nephrotoxicity and hepatotoxicity that limit its usefulness. Chronotherapy is taking circadian time into account during therapy to improve the therapeutic index, by improving efficacy and/or limiting toxicity. To this end, we tested the impact of clock time on excision repair of cisplatin-induced DNA damage at single-nucleotide resolution across the genome in mouse kidney and liver. We found that genome repair is controlled by two circadian programs. Repair of the transcribed strand (TS) of active, circadian-controlled genes is dictated by each gene's phase of transcription, which falls across the circadian cycle with prominent peaks at dawn and dusk. In contrast, repair of the nontranscribed strand (NTS) of all genes, repair of intergenic DNA, and global repair overall peaks at Zeitgeber time ZT08, as basal repair capacity, which is controlled by the circadian clock, peaks at this circadian time. Consequently, the TS and NTS of many genes are repaired out of phase. As most cancers are thought to have defective circadian rhythms, these results suggest that future research on timed dosage of cisplatin could potentially reduce damage to healthy tissue and improve its therapeutic index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.